GlassScriptPhysician profile
Robert T Morris
NPI 1659342756
$806,598.39
in general payments reported to CMS, 2019-2025
35 companies · $111K in 2025
The $111K reported for 2025 was more than what 99% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105K · 2020: $60K · 2021: $90K · 2022: $108K · 2023: $180K · 2024: $151K · 2025: $111K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $317K · Travel and Lodging: $72K · Consulting Fee: $45K · Food and Beverage: $8,626 · Education: $77.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $316,515.50 |
| Travel and Lodging | $72,230.40 |
| Consulting Fee | $45,247.00 |
| Food and Beverage | $8,625.75 |
| Education | $77.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $258,233.62 | 2020-2025 | Jemperli, Zejula |
| Abbvie INC. | $131,342.94 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $118,528.28 | 2019-2025 | Lynparza |
| Clovis Oncology, INC. | $53,794.11 | 2019-2022 | |
| Immunogen, INC. | $46,654.33 | 2023-2024 | Elahere, Elahere |
| Merck Sharp & Dohme LLC | $45,665.76 | 2019-2025 | Keytruda, Lynparza |
| Seagen INC. | $44,807.82 | 2022-2023 | Tivdak |
| Pfizer INC. | $29,853.91 | 2024-2025 | |
| Tesaro, INC. | $26,548.66 | 2019 | |
| Genmab U.S., INC. | $20,065.85 | 2023 | Tivdak |
| Aspira Women'S Health INC | $9,714.15 | 2019-2022 | |
| Daiichi Sankyo INC. | $9,184.33 | 2024-2025 | Enhertu |
| Eisai INC. | $6,180.04 | 2019-2025 | |
| Roche Diagnostics Corporation | $5,280.00 | 2021 | |
| Myriad Genetic Laboratories, INC. | $142.58 | 2023-2024 | Precisetumor, Myrisk |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $120.54 | 2019 | |
| Foundation Medicine, INC. | $95.33 | 2019 | |
| Caris Mpi, INC. | $69.09 | 2025 | Mi Cancer Seek |
| Aadi Bioscience, INC. | $58.11 | 2023 | Fyarro |
| Intuitive Surgical, INC. | $57.96 | 2023 | Da Vinci Surgical System |
| Fortovia Therapeutics, INC. | $51.84 | 2019 | |
| Smith+Nephew, INC. | $49.62 | 2023-2024 | Stravix |
| Astellas Pharma US INC | $49.52 | 2024 | Veozah |
| Lsi Solutions INC | $20.73 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.70 | 2023 | |
| Sanara Medtech INC. | $14.57 | 2024 | Celleraterx |
9 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.